Downgrade Heres How Analysts See Transgene SA Performing In The Near Term - Simply Wall St
TNG Stock | EUR 0.73 0.04 5.19% |
About 61% of Transgene's investor base is looking to short. The analysis of current outlook of investing in Transgene SA suggests that many traders are alarmed regarding Transgene's prospects. The current market sentiment, together with Transgene's historical and current headlines, can help investors time the market. In addition, many technical investors use Transgene SA stock news signals to limit their universe of possible portfolio assets.
Transgene |
Downgrade Heres How Analysts See Transgene SA Performing In The Near Term Simply Wall St
Read at news.google.com
Transgene Fundamental Analysis
We analyze Transgene's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Transgene using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Transgene based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Price To Book
Price To Book Comparative Analysis
Transgene is currently under evaluation in price to book category among its peers. Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Transgene SA Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Transgene stock to make a market-neutral strategy. Peer analysis of Transgene could also be used in its relative valuation, which is a method of valuing Transgene by comparing valuation metrics with similar companies.
Peers
Transgene Related Equities
IPH | Innate Pharma | 22.58 | ||||
AB | AB Science | 2.25 | ||||
GNFT | Genfit | 1.40 | ||||
NANO | Nanobiotix | 2.13 |
Complementary Tools for Transgene Stock analysis
When running Transgene's price analysis, check to measure Transgene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Transgene is operating at the current time. Most of Transgene's value examination focuses on studying past and present price action to predict the probability of Transgene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Transgene's price. Additionally, you may evaluate how the addition of Transgene to your portfolios can decrease your overall portfolio volatility.
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
CEOs Directory Screen CEOs from public companies around the world | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |